Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

79
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
79

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Looking Beyond the Usual Medications for Treatment of Cancer-Related Bone Pain.

The Senior care pharmacist·2025
Same author

A Parent-Metabolite Middle-Out PBPK Model for Genistein and Its Glucuronide Metabolite in Rats: Integrating Liver and Enteric Metabolism with Hepatobiliary and Enteroluminal Transport to Assess Glucuronide Recycling.

Pharmaceutics·2025
Same author

Comparative transcriptomic profiling of drug-metabolizing enzymes and drug transporters in rabbit ocular subtissues, liver, and duodenum.

Drug metabolism and disposition: the biological fate of chemicals·2025
Same author

Longitudinal curriculum design shows promise to improve pharmacogenomics education in an observational study.

Currents in pharmacy teaching & learning·2025
Same author

Interference of PFAS sorption on zeolites from natural water characteristics.

Chemosphere·2025
Same author

CYP5122A1 encodes an essential sterol C4-methyl oxidase in Leishmania donovani and determines the antileishmanial activity of antifungal azoles.

Nature communications·2024

Related Experiment Video

Updated: Mar 8, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

9.2K

Development of an In Vitro Model to Screen CYP1B1-Targeted Anticancer Prodrugs.

Zhiying Wang1, Yao Chen1, Laura M Drbohlav1

  • 11 School of Pharmacy, Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, USA.

Journal of Biomolecular Screening
|February 1, 2017
PubMed
Summary

Researchers developed a novel in vitro screening model using KLE cells for identifying Cytochrome P450 1B1 (CYP1B1)-activated anticancer prodrugs. This model effectively demonstrated prodrug cytotoxicity and apoptosis induction, highlighting its potential for drug discovery.

Keywords:
CYP1B1drug screeningendometrial cancerprodrugtargeted anticancer

More Related Videos

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
09:20

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts

Published on: June 26, 2018

8.8K
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.7K

Related Experiment Videos

Last Updated: Mar 8, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

9.2K
Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
09:20

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts

Published on: June 26, 2018

8.8K
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.7K

Area of Science:

  • Biochemistry
  • Pharmacology
  • Oncology

Background:

  • Cytochrome P450 1B1 (CYP1B1) is overexpressed in steroid hormone-related cancers, making it a key anticancer therapeutic target.
  • Prodrug strategies aim to activate anticancer agents specifically within malignant tissues via CYP1B1, minimizing systemic toxicity.

Purpose of the Study:

  • To establish and validate an in vitro screening model for identifying CYP1B1-activated anticancer prodrugs.
  • To utilize the KLE human endometrial carcinoma cell line for this screening model due to its stable CYP1B1 expression and lack of interfering CYP1A1/CYP1A2 activity.

Main Methods:

  • KLE cells were used to evaluate the efficacy of two probe prodrugs targeting CYP1B1.
  • CYP1B1 activity was chemically inhibited to serve as a control for specificity.
  • Cellular responses including cytotoxicity, cell cycle arrest (G0/G1 and S phases), and apoptosis were assessed.

Main Results:

  • Both probe prodrugs exhibited greater toxicity in KLE cells compared to CYP1B1-inhibited KLE cells.
  • The prodrugs induced significant G0/G1 cell cycle arrest and reduced the S phase population.
  • Pro-apoptotic effects were observed in KLE cells and were diminished when CYP1B1 activity was inhibited.

Conclusions:

  • The KLE cell-based model is suitable for screening and identifying novel CYP1B1-targeted anticancer prodrugs.
  • This model provides a specific and stable platform for evaluating prodrug activation and efficacy.
  • Further development and application of this model in screening chemical libraries are recommended for advancing anticancer drug discovery.